E-Lab Who's Who Flashcards
(17 cards)
Tomasz Sablinski
Tomasz Sablinski, M.D., Ph.D., is passionate about changing the paradigm of developing new drugs by converging modern information technology with drug development “know-how”, and exploiting an unlimited potential of “knowledge networking” to revolutionize drug research. He is a Founder and CEO of Transparency Life Sciences, the world’s first crowd-sourced drug development enterprise. Sablinski has been a Managing Director and Head of Celtic Therapeutic Development since 2008. Prior to joining Celtic he held positions of increasing responsibility in clinical development and medical affairs at Novartis Pharmaceuticals. During his eleven years at Novartis he was based in the US, Switzerland, and Japan. He joined pharmaceutical industry from Harvard Medical School, where he was an Instructor in Surgery from 1992 to 1997. He was a member of a Transplantation Biology Research Center team at Massachusetts General Hospital conducting pioneering work in transplantation tolerance and xenotransplantation, and earlier at the Brigham and Women’s Hospital. Sablinski is a board certified surgeon and his clinical work concentrated on renal transplantation and general surgery. He authored and co-authored over 50 scientific papers and several book chapters. He is a member of The Transplantation Society since 1992. Sablinski received his MD and PhD degrees at Warsaw Medical School, Poland.
Thomas Cirrito
Thomas P. Cirrito, Ph.D. is CEO and founder of Filament BioSolutions Inc., a medical foods company. He is also a co-founder of Immunovent, a development stage biotechnology company developing a next-generation, non-invasive allergy diagnostic. Dr. Cirrito previously served as Vice President of Research and Development and Director of Business Development at Stemline Therapeutics (NASDAQ: STML) since March 2012. Dr. Cirrito joined Stemline in 2005 as the second full-time employee, and was responsible for business development, preclinical, intellectual property, manufacturing, analytical, and operations. Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously, he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group. Dr. Cirrito received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, Missouri). He currently serves on the Scientific and Business Advisory Board of the Alzheimer’s Drug Discovery Foundation.
Linda Sharkus
Linda Sharkus, Ph.D., is Co-Founder and President of AcquiSci Inc., a medical device company that’s developing the d-OSAB™ technological platform whose applications include treatment of inflammatory diseases and purification of biological fluids. Named one of Top 25 NJ Leading Female Entrepreneurs in 2011, and Best 50 Women in Business in 2012, she’s a strategic thinker, with strong management skills, experienced at driving projects from conceptualization through commercialization, responsible for all corporate, marketing and sales, financial and investment matters. AcquiSci was recognized by NJTC Venture Conference in 2010 as the Best Life Sciences Company; in 2009 as Most Capital Efficient Company.
Francesca Reindel
Francesca Reindel is an Associate at New Science Ventures, a New York-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors. Prior to joining NSV, she was a Senior Consultant at Easton Associates (acquired by Navigant), a healthcare consulting firm that specializes in new product evaluation and strategic planning for companies across the pharmaceutical, biotechnology, and medical device industries. She graduated from Harvard University in 2011 with an A.B. degree with High Honors in Neurobiology and with a Certificate in Mind/Brain/Behavior.
Adam Goulburn
Adam Goulburn is a Senior Associate with Lux Capital, based in the firm’s New York headquarters. Adam concentrates on investments within the healthcare and life science sectors. Adam focuses on broad investment opportunities in healthcare IT, services, mobile health and therapeutics. Adam has worked extensively with a number of Lux portfolio companies including Kyruus, Kala Pharmaceuticals and Genocea Biosciences. He is also a mentor for healthcare IT incubators Blueprint Health and Healthbox. Before joining Lux, Adam was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative medicine in association with brain disorders. Originally from Australia, Adam has dual undergraduate degrees in Commerce and Science and subsequently completed his PhD at the Australian Stem Cell Centre. He has published in numerous peer reviewed scientific journals.
Adam Hanina
Adam Hanina is a founder of Ai Cure Technologies, where he also serves as chairman and chief executive officer. He has nearly 15 years of experience in the development and commercialization of health information technology and eHealth solutions for multinational companies and start-ups. As part of his extensive experience in e-Health concepts, he was responsible for developing Cerner Corporation’s European strategy and spearheading their population health solution division; founded the European eHealth Forum; and was Visiting Fellow of eHealth at Imperial College, London. Mr. Hanina has held numerous advisory board positions including for the Indian High Commission’s Healthcare, Pharmaceutical, & Biotech Committee, and for Deloitte Consulting’s Health Informatics Network for Europe (HINE). In addition, as Ai Cure CEO, Mr. Hanina is the Principal Investigator for three National Institutes of Health (NIH) innovation grants. He has also served as a subject matter expert on and reviewer of medication adherence technologies for the NIH. Prior to founding Ai Cure Technologies, Mr. Hanina was a member of West LB Mellon’s private equity group. He holds an MBA from the Wharton School of Business, an MA in management from the University of Cambridge, and a BS degree with honors from Brown University in physics and economics.
Andras Forgacs
Andras is the co-founder and CEO of Modern Meadow, a firm applying tissue engineering to develop novel biomaterials including meat and leather. Andras also co-founded Organovo, a leader in tissue engineering, which pioneered the use of 3D bioprinting to create human tissue for a range of medical applications. Previously, Andras served as a venture investor focused on early-stage technologies in the US and China. He also was a consultant with McKinsey focused on biopharma and private equity and a founding member of Citigroup’s corporate and investment banking e-commerce group. Andras holds an MBA from the Wharton and a Bachelor of Arts with honors from Harvard.
Andrea Day
Andrea Day is a healthcare executive recognized for her strategy and operations expertise. Andrea’s focus on customer needs and business objectives, her collaborative and thoughtful approach, and ease in tackling complex challenges and spotting solutions makes her a valued business partner. Andrea’s has 20 years of experience in healthcare. For 10 years at Pfizer, she led the Strategy and Analytics team supporting a $3B primary care division, and Pfizer’s patient assistance and reimbursement programs. She garnered expertise in sales strategy, planning, and analysis, managing vendor operations, contract negotiations, operations improvement, finance, marketing, communications, and advocacy. Prior to Pfizer, Andrea led the healthcare practice at Siegel & Gale consultancy. Her steadfast focus on customer needs driving strategy and operations comes from her rigorous brand management training with Kraft Foods. Andrea earned her MBA from The Wharton School, and her BA in Biology from Colgate University.
Anton Xavier
Anton Xavier is a senior scientist at Pfizer Oncology (WW R&D). His focus is in bio-therapeutic early discovery. This stage of development includes novel target discovery, small scale therapeutic development, MOA, and preclinical work. In addition to his R&D background, Anton has business experience particularly within biotech venture evaluation and mentoring.
Arnold Burstein
Mr. Burstein is a pharmaceutical executive with over 25 years of experience in marketing, business development, and technical operations. A major portion of his career was spent at Schering-Plough where he held a number of executive positions including Vice President of OTC Products Marketing, Vice President Manufacturing Development, and Senior Director, Marketing Services. Mr. Burstein also served as Executive Vice President International Operations and Business Development at Taro Pharmaceuticals. In this capacity, he established a distribution network in multiple Caribbean, Latin American, and Pacific Rim countries. Mr. Burstein is currently with the BioClara Group, a New York City based biopharmaceutical consulting company, focusing on business development, technology assessment, and life cycle management. As Executive Vice President, he is responsible for commercial development and key account management. Mr. Burstein holds a BA in Economics from Brooklyn College of the City University of New York, and an MBA in Marketing/Management from New York University.
Bibhash Mukhopadhyay
Bibhash is with the Business Development Group at Johnson & Johnson’s Global Surgery Division. His responsibilities include identifying and building strategies around new growth space opportunities and leading cross functional teams for deal sourcing, evaluation & transactions for investment, licensing & acquisition activities. Prior to joining J&J, he gained experience in venture investing at Burrill & Co, in starts up both as a founder of a medtech company & advisor to a biotech. His academic research background includes understanding pathophysiology of retinal diseases using tools of cell biology & mathematical modeling.
Brendan Rae
In addition to practicing patent law, Dr. Rae has worked as a licensing and business development professional in the pharmaceutical and biotechnology industries over the last 15 years. In this capacity, he has successfully sourced new products, led due diligence and commercial evaluation teams, and negotiated and executed agreements in the US, Europe and Far East. Most recently, Dr. Rae was the Chief Business Officer of Vivaldi Biosciences Inc., an influenza vaccine development company headquartered in New York City. Prior to that, he served, from 2005 to 2010, as Senior Vice President, Licensing and Business Development at VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of therapies for the treatment of cardiovascular disease. Dr. Rae’s pharmaceutical licensing experience was gained at Hoffman-La Roche Ltd., where he directed the company’s in-licensing and out-licensing activities from 1996 to 2003, and at Purdue Pharma L.P. Dr. Rae practiced patent law at the firm of Amster, Rothstein & Ebenstein, LLP. Dr. Rae obtained his Bachelor of Science degree in Microbiology from Glasgow University, and was awarded a Ph.D. by the Institute of Virology in Glasgow, Scotland. He was a Postdoctoral Fellow at the Roche Institute of Molecular Biology. Dr. Rae has served as an Adjunct Assistant Professor, Department of Microbiology and Immunology, at the New York Medical College since 1989, and a Visiting Professor in the School of Host Infection and Immunity at Liverpool University since 2008. Dr. Rae earned his Juris Doctor degree from Seton Hall Law School in Newark, New Jersey.
Bryan Czyzewski
Bryan is a scientist in the Molecular Oncology group at Kadmon Corporation and utilizes a variety of biochemical and structural biology approaches in advancing preclinical candidates. Prior to Kadmon, Bryan received his PhD in Cell Biology from NYU Medical School of Medicine, and made important advances in ion channel and membrane protein structural biology. Prior to NYU, Bryan studied various oncogenes and tumor suppressors using biophysical methods at Memorial Sloan-Kettering Cancer Center.
Emily Walsh
Over the past 8 years, Emily has held a number of roles in drug discovery program management. Her first was at the Novartis Drug Discovery Incubator within Novartis Institutes for Biomedical Research. This group sought to internally “partner” high-risk discovery programs within Novartis for full clinical development. Subsequently, Emily was responsible for business, financial, alliance and scientific program management across a number of research and development programs at Alnylam Pharmaceuticals. After Alnylam, Emily founded Tremont Therapeutics, a small virtual biotech focused on identifying and developing promising therapeutics from academia from mid-discovery through human proof of concept. Since 2011, Emily has served as a drug development and program management consultant for a range of clients from early startups to big pharma.
Francesca Milletti
Francesca Milletti is Data Scientist at Roche (New York, NY). She joined Roche in 2010 after a postdoctoral fellowship at Novartis, Basel. Before that, she was a visiting student at the University of California, San Francisco (2008). She received her PhD and undergraduate degree in Chemistry from the University of Perugia, Italy, where she developed computational tools for pKa prediction and tautomer enumeration. Her current research focuses on novel computational methods for drug discovery, with a special interest on drug repurposing and NGS for clinical development.
Erica Winter
Erica holds a M.S. degree in Biochemistry and Molecular Biology from UC Riverside and a Pharm.D. from UC San Diego. She first joined Roche Clinical Pharmacology in 2008 as a Post-doctoral Fellow. Erica has worked on a number of biologic (antibodies, proteins) and small molecule projects in oncology, inflammation and virology. Her experience in drug development spans early phase: bridging from pre-clinical to clinical, phase I/II study design, dose finding activities, modeling and simulation to late phase and NDA filing. She recently re-joined Roche/Genentech after working for a small company in NYC that specialized in transdermal drug development.
Yuval Cohen
Dr. Cohen joined the Company in 2013. Prior to joining the Company he was the President and co-founder of Morria Biopharmaceuticals PLC. Starting as a small startup with seed financing, under Dr. Cohen’s leadership Morria went public on the London Stock Exchange and successfully developed five novel anti-inflammatory drug candidates with two reaching Phase 2b stages focusing on allergies and autoimmune diseases of the skin, airways, digestive tract and eye. Dr. Cohen participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fund raising. During his career Dr Cohen has successfully completed a public listing in the US. Dr. Cohen has a PhD, summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents.
